JW Asset Management LLC Buys 22,000 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

JW Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 22,000 shares of the company’s stock, valued at approximately $1,641,000. Kiniksa Pharmaceuticals International makes up 0.7% of JW Asset Management LLC’s portfolio, making the stock its 15th largest position.

A number of other institutional investors also recently added to or reduced their stakes in KNSA. Curry Webb Wealth Management LLC bought a new position in Kiniksa Pharmaceuticals International in the 3rd quarter valued at about $29,000. Allworth Financial LP increased its stake in Kiniksa Pharmaceuticals International by 42.0% during the 2nd quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after buying an additional 134 shares during the period. Nykredit A S bought a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth about $34,000. Jacobi Capital Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth about $48,000. Finally, KBC Group NV bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth about $34,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $96.28 on Friday. The firm’s 50 day moving average is $81.86 and its 200-day moving average is $62.44. The stock has a market capitalization of $7.56 billion, a P/E ratio of 74.06 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 12-month low of $37.02 and a 12-month high of $99.31.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. As a group, equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Canaccord Genuity Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wedbush upped their target price on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 28th. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, October 28th. The Goldman Sachs Group lifted their price target on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Finally, Citigroup boosted their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and a consensus price target of $100.57.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael Megna sold 36,260 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $94.43, for a total value of $3,424,031.80. Following the transaction, the chief accounting officer owned 12,697 shares in the company, valued at approximately $1,198,977.71. The trade was a 74.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John Paolini sold 77,587 shares of the company’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $93.02, for a total value of $7,217,142.74. Following the completion of the transaction, the insider directly owned 69,922 shares in the company, valued at $6,504,144.44. This represents a 52.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 842,302 shares of company stock valued at $78,587,130 in the last 90 days. 51.98% of the stock is owned by corporate insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.